Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Aktis Oncology announced a two-trial clinical development strategy for AKY-2519, enabling evaluation in multiple patient segments. The company initiated a Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC) and expects preliminary data in 2027. Aktis also plans to present clinical imaging and dosimetry data for AKY-2519 at the upcoming ASCO Annual Meeting, which will provide initial insights into the drug's biodistribution and absorbed doses.
Key figures
- Net loss
- 18325000
- Cash position
- 538484000
- G and a expenses
- 5897000
- R and d expenses
- 20036000
- Collaboration revenue
- 3227000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.